Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A study found that only 15% of men in North Carolina with low or intermediate-risk prostate cancer who chose active surveillance followed recommended monitoring guidelines. This suggests that patients may not be adhering to the guidelines, which include regular PSA tests and biopsies. The study's authors call for further research into ...
Researchers at Duke University Medical Center discovered how prostate cancer cells develop to mimic bone-forming cells, enabling proliferation in the bone microenvironment. This understanding could lead to more effective use of radium-233 and development of new therapies to treat or prevent prostate cancer spread to bone.
A new study found that black men with low-risk prostate cancer are 16% less likely to adopt active surveillance than non-black men, despite similar rates of overall active surveillance. The disparity is attributed to socioeconomic and insurance barriers that deter black patients from accessing follow-up care.
A new device forces cells through tiny channels, detecting blebbing in cancer cells to identify metastatic prostate cancer. Highly metastatic cells exhibit more blebbing than normal or less-metastatic cells.
Researchers at Boston University School of Medicine have discovered that inhibiting the BRD4 protein can consistently regulate prostate cancer cell migration and invasion. The study provides promising insights into preventing the spread of castration-resistant prostate cancer (CRPC), a highly aggressive form of the disease.
Researchers have identified a promising therapeutic target for metastatic prostate cancer by inhibiting the PHLPP2 protein, which stabilizes the oncogenic protein MYC. This finding has implications for treating other cancers driven by MYC and could lead to efficient new drugs.
Researchers discovered that blocking PHLPP2 enzyme halts prostate cancer growth and metastasis without signs of toxicity in mice or human cells. This finding presents a promising approach for treating prostate cancer and potentially other types of cancers.
The Damon Runyon Physician-Scientist Training Award provides physicians with research skills and experience to become leaders in translational and clinical research. The award addresses financial burdens that deter physicians from pursuing a research career, offering up to $460,000 over four years.
Researchers found higher levels of aneuploidy lead to greater lethality risk among prostate cancer patients, suggesting a possible way to predict prognosis and inform treatment. The study also identified chromosomes 7 and 8 as commonly aneuploid in prostate tumors.
Abnormal chromosome number abnormalities are linked to increased risk of lethal disease in prostate cancer patients. Patients with five or more predicted aneuploidy alterations had a 5.3 times higher odds of lethal cancer during follow-up.
A new study published in the Journal of Urology found that transperineal prostate biopsies (TPBx) under local anesthetic are the safest method for testing and diagnosing prostate cancer, with fewer complications and improved patient tolerability.
Researchers discovered that low levels of syntaphilin at the central core of prostate tumors correlate with increased risk of metastasis. The biomarker may identify patients who require more aggressive management and treatment.
Research reveals men treated for benign prostatic hyperplasia (BPH) with 5-α-reductase inhibitors experienced a two-year delay in prostate cancer diagnosis and were twice as likely to have advanced disease. PSA suppression from these medications led to delays in diagnosis, potentially resulting in worsened clinical outcomes.
A new imaging technique using subharmonic contrast-enhanced ultrasound may help detect prostate cancer in patients where MRI is negative. The study, to be presented at the ARRS Annual Meeting, found that the technique detected PCa in 9 of 31 patients with a prior negative MRI or biopsy.
A study of 429 men with metastatic castration-resistant prostate cancer found correlations between specific genetic alterations and clinical outcomes. The loss of the RB1 tumor suppressor gene was significantly correlated with poor survival in patients treated with androgen receptor signaling inhibitors.
Researchers have identified a gene mutation in prostate cancer that is linked to poor survival and increased relapse rates. The study found that men with this mutation are more than three times as likely to die and nearly seven times as likely to relapse on standard treatments.
Researchers at Karolinska Institutet have identified blood-based biomarkers that can determine which patients with advanced prostate cancer will benefit from continued hormonal therapy. The study suggests that patients with a normal TP53 gene and fewer AR resistance markers may benefit more from treatment.
A single high-dose treatment has shown promise in treating men with low-risk prostate cancer, reducing the need for multiple visits to the hospital. After two years, 94% of patients showed no sign of cancer returning, while those with medium-risk cancer saw a 95% success rate.
Research by UBC's Men's Health Research Program reveals that many men struggle with understanding prostate cancer diagnosis and treatment options. The study highlights the importance of health literacy in making informed decisions and managing personal health.
Global prostate cancer incidence and mortality rates are decreasing or stabilizing, with the US experiencing a significant decline. The study highlights improvements in detection practices and treatment, but notes that PSA screening may contribute to diagnosis at later stages and higher mortality rates.
A recent UBC study found that a 'reduced workload' program is the best option for men recovering from a radical prostatectomy, reducing the risk of burnout and promoting full recovery. The researchers recommend that patients have an open conversation with their employer before surgery to come up with a plan for a gradual return to work.
Researchers at the University of Bradford discovered a protein, EN2, released by cancer cells that alters normal cell behavior, promoting tumour growth and evading the immune system. The study found that both cancer and normal cells take up the protein, leading to changes in shape or fusion, allowing cancer cells to reactivate and spread.
Researchers from University of Texas Medical Branch at Galveston developed a laser treatment that selectively destroys cancerous prostate tissue while preserving erectile and urinary functions. This technique is shown to be as effective as complete removal or radiation therapy with improved quality of life.
Researchers at University of Alabama at Birmingham discovered androgen receptor imports into mitochondria, where it regulates multiple mitochondrial processes. This finding may lead to new treatment targets for castration-resistant prostate cancer.
Scientists have identified two coffee compounds, kahweol acetate and cafestol, which inhibit the growth of prostate cancer cells in cell culture and animal models. The study's findings suggest that these compounds may be used to treat drug-resistant prostate cancer, with further investigation needed.
Researchers found that men with high neuroticism are more likely to experience adverse events after prostate cancer surgery, such as erectile dysfunction and incontinence. The study suggests that personality tests may be a valuable tool for identifying at-risk patients and improving care.
A new web tool, PREDICT Prostate, helps patients make informed decisions about treatment for early prostate cancer by providing a personalized prognosis and treatment options. The tool uses data from over 10,000 UK men to estimate survival rates and potential side effects of treatment.
A new risk model developed by researchers can predict the survival of non-metastatic prostate cancer patients and the effect of different treatment approaches on survival. The PREDICT Prostate model uses data from over 10,000 men diagnosed with non-metastatic prostate cancer and has been validated in an external cohort.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
A phase III trial found hypofractionated radiotherapy (H-RT) to have similar QOL outcomes as conventional radiotherapy (C-RT) in men with low risk prostate cancer. H-RT delivers a total dose over a shorter period, reducing treatment duration and potential side effects.
Use of active surveillance for low-risk localized prostate cancer increased significantly between 2010 and 2015, becoming the dominant management strategy. Surgery rates declined among men with low-risk disease, while increasing in high-risk patients.
The use of active surveillance for low-risk prostate cancer nearly tripled between 2010 and 2015, with 42.1% of men adopting this strategy. This increase is associated with a favorable prognosis and reduced toxicity from treatment.
A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period and still have the same successful outcomes as from a much longer course of treatment. The study analyzed data from 2,142 men treated with stereotactic body radiotherapy for...
A new machine-learning framework distinguishes between low- and high-risk prostate cancer with higher precision than existing tools. The framework aims to provide radiologists and clinicians with a sound prediction tool for personalized patient care.
A new study suggests that enlarged prostates could impede tumor growth in prostate cancer patients. Computer simulations found that the mechanical stresses from an enlarging prostate keep tumors small. The findings challenge traditional treatments that involve downsizing the prostate.
Researchers at the University of Seville have characterized the normal electrical activity in PC-3 prostate cancer cells, showing a low-frequency pattern between 0.1 and 10 Hz. This study aims to explore the relationship between electrical patterns and cell proliferation, with potential applications for medicine delivery.
A team of scientists at Queen Mary University of London is working on a novel approach to treat prostate cancer using a modified type of flu virus. The goal is to develop a new treatment that can target and kill cancer cells while leaving non-cancer cells unharmed. By modifying the virus to deliver it via the blood, the researchers hop...
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
Researchers at UIC will study mangosteen's phytochemicals and their impact on prostate cancer cells, with the goal of developing a new treatment approach. The $1.7M grant from NCI aims to investigate the unique xanthones in mangosteen that promote androgen receptor degradation.
Researchers have discovered that the GREB1 gene amplifies androgen receptor output in human prostate cancer cells, contributing to antiandrogen resistance. Inhibiting GREB1 converts high-AR output cells to low-output states, improving enzalutamide treatment effectiveness.
Researchers identified a link between BRCA2 mutations and aggressive prostate cancer in men, increasing their risk of developing other cancers. The study also found that patients with BRCA2 mutations have poorer treatment responses and outcomes.
Researchers identified genetic alterations in low-risk prostate cancers that may indicate higher-risk cancer presence, guiding men to consider treatment. The study suggests a potential test to validate these alterations, enabling personalized treatment decisions.
Recent advancements in prostate imaging modalities have significantly enhanced the diagnosis of prostate cancer. Androgen receptor-based imaging is emerging as a promising approach for non-invasive detection using non-steroidal antiandrogen agents.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
A recent study suggests that black men diagnosed with low-risk prostate cancer (Gleason score 6) may have a more aggressive form of the disease, leading to higher mortality rates compared to non-black men. The research found a significant disparity in prostate cancer death rates between black and non-black patients with Gleason 6 cancers.
A new assay can analyze small amounts of material to estimate metastatic risk, enhancing prostate cancer evaluation. The Next-Generation Copy Number Alteration (NG-CNA) assay is a targeted amplification sequencing technique that can process samples faster and decrease the cost per sample.
A 29-year study found that only 12% of men with advanced prostate cancer were saved from dying by surgery, while 80% had died after 29 years. Surgery did extend life expectancy by 2.9 years, but also came with significant side effects.
A team of researchers has created a computer model using cancer patient data to predict the course of disease for prostate cancer. The model, currently being implemented at a clinic in Germany, can identify key mutations that trigger the disease.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A 20-year study from Northwestern Medicine found men with inflammatory bowel disease have four to five times higher risk of prostate cancer and elevated PSA values. Researchers are now investigating the mechanism behind gut inflammation leading to prostate cancer.
A new medical software system, SmartTarget, enhances prostate cancer detection by overlaying MRI scans onto ultrasound images, guiding surgeons during biopsies. The technology has shown that combining both techniques can detect clinically relevant cancers missed with current methods.
A study of 150 popular YouTube videos on prostate cancer found that 77% had factual errors or biased content, while only 53% adequately described potential harms and side effects. Researchers urge viewers to consult credible sources for accurate information on prostate cancer.
A new study has identified a novel molecular driver of lethal prostate cancer and a molecule that could be used to attack it. The findings, if confirmed in humans, could lead to more effective ways to control certain aggressive types of prostate cancer.
Researchers found that combining surgery with post-operative low-dose radiation and hormone therapy reduces prostate cancer death risk to less than 10% for men with aggressive prostate cancer. In contrast, surgery alone increases the risk of death from prostate cancer within five years.
A study led by CNIO has defined a blood-based biomarker that can determine the most effective treatment for castration-resistant prostate cancer patients. The biomarker, which analyzes the presence of a specific gene in circulating tumour DNA, shows promise for improved survival rates and personalized therapy.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
A study of 1244 patients found a 72% higher risk of heart failure in those receiving androgen deprivation therapy compared to non-users. The researchers recommend counseling patients on modifiable heart failure risk factors and providing cardiovascular examinations.
Researchers will identify biomarkers for DNA repair defects in tumors, enabling faster decision-making on treatment choices. A clinical trial will test carboplatin therapy's effectiveness in advanced prostate cancer.
A study found that men with prostate cancer value quality of life and will trade off survival odds for fewer side effects, including urinary incontinence and impotence. The research suggests that patients may prefer less invasive treatments like focal therapy or active surveillance to reduce harm.